Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Membrane permeability, a pivotal function involved in antibiotic resistance and virulence in Enterobacter aerogenes clinical isolates.

Lavigne JP, Sotto A, Nicolas-Chanoine MH, Bouziges N, Bourg G, Davin-Regli A, Pagès JM.

Clin Microbiol Infect. 2012 Jun;18(6):539-45. doi: 10.1111/j.1469-0691.2011.03607.x.

2.

An adaptive response of Enterobacter aerogenes to imipenem: regulation of porin balance in clinical isolates.

Lavigne JP, Sotto A, Nicolas-Chanoine MH, Bouziges N, Pagès JM, Davin-Regli A.

Int J Antimicrob Agents. 2013 Feb;41(2):130-6. doi: 10.1016/j.ijantimicag.2012.10.010.

PMID:
23280442
3.

Imipenem and expression of multidrug efflux pump in Enterobacter aerogenes.

Bornet C, Chollet R, Malléa M, Chevalier J, Davin-Regli A, Pagès JM, Bollet C.

Biochem Biophys Res Commun. 2003 Feb 21;301(4):985-90.

PMID:
12589810
4.

Successive emergence of Enterobacter aerogenes strains resistant to imipenem and colistin in a patient.

Thiolas A, Bollet C, La Scola B, Raoult D, Pagès JM.

Antimicrob Agents Chemother. 2005 Apr;49(4):1354-8.

5.

Identification and evolution of drug efflux pump in clinical Enterobacter aerogenes strains isolated in 1995 and 2003.

Chevalier J, Mulfinger C, Garnotel E, Nicolas P, Davin-Régli A, Pagès JM.

PLoS One. 2008 Sep 12;3(9):e3203. doi: 10.1371/journal.pone.0003203.

6.

Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes.

Mallea M, Chevalier J, Bornet C, Eyraud A, Davin-Regli A, Bollet C, Pagès JM.

Microbiology. 1998 Nov;144 ( Pt 11):3003-9.

PMID:
9846735
7.

In vivo development of carbapenem resistance in clinical isolates of Enterobacter aerogenes producing multiple beta-lactamases.

Chen YG, Zhang Y, Yu YS, Qu TT, Wei ZQ, Shen P, Li LJ.

Int J Antimicrob Agents. 2008 Oct;32(4):302-7. doi: 10.1016/j.ijantimicag.2008.02.014.

PMID:
18556176
8.

Membrane permeability and regulation of drug "influx and efflux" in enterobacterial pathogens.

Davin-Regli A, Bolla JM, James CE, Lavigne JP, Chevalier J, Garnotel E, Molitor A, Pagès JM.

Curr Drug Targets. 2008 Sep;9(9):750-9. Review.

PMID:
18781921
9.

In Vivo Evolution of Bacterial Resistance in Two Cases of Enterobacter aerogenes Infections during Treatment with Imipenem.

Philippe N, Maigre L, Santini S, Pinet E, Claverie JM, Davin-Régli AV, Pagès JM, Masi M.

PLoS One. 2015 Sep 23;10(9):e0138828. doi: 10.1371/journal.pone.0138828.

10.

Emergence of imipenem resistance in clinical Escherichia coli during therapy.

Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodríguez MC, Velasco M, Saavedra JM, Pérez-Vázquez M, García-Cobos S, Martínez-Martínez L, Campos J.

Int J Antimicrob Agents. 2008 Dec;32(6):534-7. doi: 10.1016/j.ijantimicag.2008.06.012.

PMID:
18775649
11.

Molecular typing and characterization of extended-spectrum TEM, SHV and CTX-M beta-lactamases in clinical isolates of Enterobacter cloacae.

Biendo M, Manoliu C, Laurans G, Castelain S, Canarelli B, Thomas D, Hamdad F, Rousseau F, Eb F.

Res Microbiol. 2008 Nov-Dec;159(9-10):590-4. doi: 10.1016/j.resmic.2008.09.003.

PMID:
18845248
12.

Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.

Bialek S, Lavigne JP, Chevalier J, Marcon E, Leflon-Guibout V, Davin A, Moreau R, Pagès JM, Nicolas-Chanoine MH.

Antimicrob Agents Chemother. 2010 Oct;54(10):4373-8. doi: 10.1128/AAC.01607-09.

13.

Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with decreased expression of OmpF and OmpC porin analogs.

Yigit H, Anderson GJ, Biddle JW, Steward CD, Rasheed JK, Valera LL, McGowan JE Jr, Tenover FC.

Antimicrob Agents Chemother. 2002 Dec;46(12):3817-22.

14.

Consecutive mutations leading to the emergence in vivo of imipenem resistance in a clinical strain of Enterobacter aerogenes.

Tzouvelekis LS, Tzelepi E, Kaufmann ME, Mentis AF.

J Med Microbiol. 1994 Jun;40(6):403-7.

PMID:
8006932
15.

Genetic characterization of tigecycline resistance in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes.

Veleba M, De Majumdar S, Hornsey M, Woodford N, Schneiders T.

J Antimicrob Chemother. 2013 May;68(5):1011-8. doi: 10.1093/jac/dks530.

16.

Imipenem resistance of enterobacter aerogenes mediated by outer membrane permeability.

Bornet C, Davin-Regli A, Bosi C, Pages JM, Bollet C.

J Clin Microbiol. 2000 Mar;38(3):1048-52.

17.

Clinical and bacteriological study of nosocomial infections due to Enterobacter aerogenes resistant to imipenem.

de Champs C, Henquell C, Guelon D, Sirot D, Gazuy N, Sirot J.

J Clin Microbiol. 1993 Jan;31(1):123-7.

18.

Prevalence of outer membrane porin alteration in beta-lactam-antibiotic-resistant Enterobacter aerogenes.

Charrel RN, Pagès JM, De Micco P, Mallea M.

Antimicrob Agents Chemother. 1996 Dec;40(12):2854-8.

19.

Chloroquinolines block antibiotic efflux pumps in antibiotic-resistant Enterobacter aerogenes isolates.

Ghisalberti D, Mahamoud A, Chevalier J, Baitiche M, Martino M, Pagès JM, Barbe J.

Int J Antimicrob Agents. 2006 Jun;27(6):565-9.

PMID:
16707249
20.

Emergence of cross-resistance to imipenem and other beta-lactam antibiotics in Pseudomonas aeruginosa during therapy.

Pagani L, Landini P, Luzzaro F, Debiaggi M, Romero E.

Microbiologica. 1990 Jan;13(1):43-53.

PMID:
2155376
Items per page

Supplemental Content

Support Center